Taysha Gene Therapies Announces Commercial Supply Agreement With Catalent For Rett Syndrome Gene Therapy TSHA-102 Ahead Of Potential FDA Approval

Loading news article.

Taysha Gene Therapies Announces Commercial Supply Agreement With Catalent For Rett Syndrome Gene Therapy TSHA-102 Ahead Of Potential FDA Approval | WAPE

Taysha Gene Therapies Announces Commercial Supply Agreement With Catalent For Rett Syndrome Gene Therapy TSHA-102 Ahead Of Potential FDA Approval

Article summary

Related companies

Comments —